v3.25.2
FINANCIAL STATEMENT RESTATEMENT (Details 1) - USD ($)
 3 Months Ended 6 Months Ended
Apr. 30, 2025
Jan. 31, 2025
Apr. 30, 2024
Jan. 31, 2024
Apr. 30, 2025
Apr. 30, 2024
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Beginning Additional Paid-in Capital - Balance at October 31, 2023   $ 42,502,997     $ 42,502,997  
Beginning Accumulated Deficit - Balance at October 31, 2023   (44,326,326)     (44,326,326)  
Net loss for the six months ended April 30, 2024 $ (470,066) $ (634,338) $ (570,855) $ (507,073) (1,104,404) $ (1,077,928)
Ending Additional paid in capital - Balance at April 30, 2024 43,649,927       43,649,927  
Ending Accumulated Deficit - Balance at April 30, 2024 $ (45,430,730)       $ (45,430,730)  
Previously Reported [Member]            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Beginning Additional Paid-in Capital - Balance at October 31, 2023     41,171,311 41,079,902   41,079,902
Beginning Accumulated Deficit - Balance at October 31, 2023     (42,132,662) (41,609,945)   (41,609,945)
Beginning Total Stockholders’ Deficit - Balance at October 31, 2023     $ (489,418) (92,201)   $ (92,201)
Series A preferred issued pursuant to patent agreement, shares     10,000,000     10,000,000
Series A preferred issued pursuant to patent agreement, amount     $ 10,000     $ 10,000
Net loss for the six months ended April 30, 2024     565,033     1,087,817
Ending Additional paid in capital - Balance at April 30, 2024     41,291,591 41,171,311   41,291,591
Ending Accumulated Deficit - Balance at April 30, 2024     (42,697,762) (42,132,662)   (42,697,762)
Ending Total Stockholders’ Deficit - Balance at April 30, 2024     (920,868) (489,418)   (920,868)
Revision of Prior Period, Adjustment [Member]            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Beginning Additional Paid-in Capital - Balance at October 31, 2023     390,275 390,275   390,275
Beginning Accumulated Deficit - Balance at October 31, 2023     (470,515) (486,159)   (486,159)
Beginning Total Stockholders’ Deficit - Balance at October 31, 2023     $ (85,240) (100,884)   $ (100,884)
Series A preferred issued pursuant to patent agreement, shares     (5,000,000)     (5,000,000)
Series A preferred issued pursuant to patent agreement, amount     $ (5,000)     $ (5,000)
Net loss for the six months ended April 30, 2024     5,822     (9,889)
Ending Additional paid in capital - Balance at April 30, 2024     390,275 390,275   390,275
Ending Accumulated Deficit - Balance at April 30, 2024     (476,270) (470,515)   (476,270)
Ending Total Stockholders’ Deficit - Balance at April 30, 2024     (90,995) (85,240)   (90,995)
As Restated [Member]            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Beginning Additional Paid-in Capital - Balance at October 31, 2023     41,561,586 41,470,177   41,470,177
Beginning Accumulated Deficit - Balance at October 31, 2023     (42,603,177) (42,096,104)   (42,096,104)
Beginning Total Stockholders’ Deficit - Balance at October 31, 2023     $ (574,658) (193,085)   $ (193,085)
Series A preferred issued pursuant to patent agreement, shares     5,000,000     5,000,000
Series A preferred issued pursuant to patent agreement, amount     $ 5,000     $ 5,000
Net loss for the six months ended April 30, 2024     570,855     1,077,928
Ending Additional paid in capital - Balance at April 30, 2024     41,681,866 41,561,586   41,681,866
Ending Accumulated Deficit - Balance at April 30, 2024     (43,174,032) (42,603,177)   (43,174,032)
Ending Total Stockholders’ Deficit - Balance at April 30, 2024     $ (1,011,863) $ (574,658)   $ (1,011,863)